Co-Diagnostics Financials - Benzinga

Co-Diagnostics Inc

CODXNASDAQ

Trade with Public

Trade with Public

$1.42

-0.09-5.96%

At close: Aug 6, 5:00 PM EST

$1.41

-0.01-0.70%

After Hours: 7:14 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Co-Diagnostics Financials

Co-Diagnostics (CODX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Co-Diagnostics Q1 EPS $(4.06) Misses $(3.90) Estimate, Sales $145.954K Miss $163.500K Estimate

Benzinga Newsdesk

Earnings Scheduled For May 14, 2026

Benzinga Insights

PRO
Co-Diagnostics Q4 EPS $(16.65) Down From $(10.82) YoY, Sales $263.922K Up From $149.325K YoY

Co-Diagnostics (OTC:CODX) reported quarterly losses of $(16.65) per share. This is a 53.88 percent decrease over losses of $(10.82) per share from the same period last year. The company reported $263.922 thousand in

Benzinga Newsdesk

Earnings Scheduled For March 31, 2026

Benzinga Insights

Nasdaq Down Over 1%; XPeng Shares Fall After Q4 Results

U.S. stocks traded lower, with Dow falling over 100 points. Energy shares climbed 1%, while consumer stocks dropped 1.3%. Xpeng shares fell 7% after weak sales results. Scholastic soared 12% and Super Micro Computer dropped 27%.

Avi Kapoor

PRO
Co-Diagnostics Q3 EPS $(0.16) Beats $(0.17) Estimate, Sales $145.380K Miss $150.000K Estimate

Co-Diagnostics (NASDAQ:CODX) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.17) by 8.57 percent. This is a 50 percent increase over losses of $(0.32) per share from the

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved